✦ LIBER ✦

The Oral NK1Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

✍ Scribed by Dr Ronald de Wit, Paul J. Hesketh, David Warr, Kevin Petty…

Book ID: 120840544
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2005
Tongue: English
Weight: 170 KB
Volume: 4
Category: Article
ISSN: 0099-7374
DOI: 10.2165/00024669-200504010-00003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Palonosetron plus 3-day aprepitant and d

Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy

✍ Flavia Longo; Giovanni Mansueto; Vittoria Lapadula; Rita De Sanctis; Silvia Quad 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 169 KB

Establishing the dose of the oral NK1 an

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting

✍ Sant P. Chawla; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Cindy Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

## Abstract ## BACKGROUND The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and vomiting when it is given with a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone. The current study sought to

Analysis of aprepitant for prevention of

Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy

✍ Molassiotis, Alex; Nguyen, Allison Martin; Rittenberg, Cynthia N; Makalinao, Ale 📂 Article 📅 2013 🏛 Future Medicine 🌐 English ⚖ 398 KB

Cost-Effectiveness of Aprepitant for the

Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy

✍ Susan Moore; John Tumeh; Steven Wojtanowski; Christopher Flowers 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 743 KB

3072 Palonosetron plus a three-day aprep

3072 Palonosetron plus a three-day aprepitant and dexamethasone schedule to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy

✍ G. Mansueto; F. Longo; R. De Sanctis; V. Lapadula; S. Quadrini; I. D'Antoni; R. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 45 KB

9048 Aprepitant for the prevention of ch

9048 Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer

✍ Rapoport, B.; Boice, J.A.; Brown, C.; Street, J.C.; Hardwick, J.S.; Carides, A.D 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 67 KB